Keyphrases
Disease Progression
100%
Targeted Therapy
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Pazopanib
100%
Progressive Disease
60%
Adverse Events
60%
Progression-free Survival
40%
Hypertension
20%
Diarrhea
20%
Placebo
20%
Median Overall Survival
20%
Anorexia
20%
Treatment-related Mortality
20%
Consecutive Patients
20%
Tyrosine Kinase Inhibitor
20%
Kaplan-Meier Method
20%
Overall Survival
20%
Safety Data
20%
Hypothyroidism
20%
Nausea-vomiting
20%
Radiologists
20%
Partial Response
20%
Tumor Response
20%
Response Evaluation Criteria in Solid Tumors (RECIST)
20%
Elevated Transaminases
20%
Median Progression-free Survival
20%
Treatment-naïve
20%
Medicine and Dentistry
Targeted Therapy
100%
Disease Exacerbation
100%
Clear Cell Renal Cell Carcinoma
100%
Pazopanib
100%
Adverse Event
60%
Progressive Disease
60%
Progression Free Survival
60%
Overall Survival
40%
Neoplasm
20%
Diarrhea
20%
Placebo
20%
Cytokine
20%
Tyrosine-Kinase Inhibitor
20%
Kaplan Meier Method
20%
Cancer Staging
20%
Nausea
20%
Elevated Transaminases
20%
Hypothyroidism
20%
Anorexia
20%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Exacerbation
100%
Renal Cell Carcinoma
100%
Pazopanib
100%
Adverse Event
60%
Disease
60%
Progression Free Survival
60%
Overall Survival
40%
Placebo
20%
Diarrhea
20%
Neoplasm
20%
Cytokine
20%
Anorexia
20%
Protein Tyrosine Kinase Inhibitor
20%
Cancer Staging
20%
Nausea
20%
Hypothyroidism
20%
Hypertransaminasemia
20%